Story perspectives
FDA Approves Wegovy for Treating Metabolic Liver Disease
8/16/2025
34 7
1 of 1
Story summary
- The FDA has granted accelerated approval for Wegovy by Novo Nordisk to treat metabolic dysfunction-associated steatohepatitis (MASH), which affects 5% of U.S. adults.
- Wegovy is the first GLP-1 therapy approved for MASH and has demonstrated improved liver conditions in clinical trials.
- There are concerns from critics regarding the effectiveness of accelerated approvals.
